Advanced imaging for oncology staging and follow-up
Lectures
1
Introduction by the moderator - Marius E. Mayerhöfer, Vienna / AT
02:00
2
A novel non-invasive approach to cancer of unknown primary: AI can detect CT morphological differences between primary tumours and metastases across tumour types - Zuhir Elkarghali, Amsterdam / NL
08:00
3
Magnetic resonance imaging (MRI) for staging melanoma patients in direct comparison to computed tomography (CT): results from a prospective positron-emission tomography PET/CT and PET/MRI study - Cecilia Zhang, Tuebingen / DE
08:00
4
Identification of early CT imaging response predictors after CAR T-cell therapy - Michael Winkelmann, Munich / DE
08:00
5
CT‑based radiomics score of PET-negative residual CT Masses: a potential biomarker for the prediction of relapse‑free survival in lymphoma patients showing complete metabolic response - Seung Ha Cha, Seoul, Seocho-gu / KR
08:00
6
Preliminary whole-body MRI study for evaluation of minimal residual disease in a group of multiple myeloma patients - Valentina Angelini, Napoli / IT
08:00
7
Ultra low dose whole-body computed tomography protocol optimisation for patients with plasma cell disorders: diagnostic accuracy and effective dose analysis from a reference centre - Davide Tore, Asti / IT
08:00
8
Iodine quantification on multi-vendor DECT platforms: inter-scanner variability and impact of normalisation - Simon Lennartz, Köln / DE
08:00
9
Investigating the validity of computed tomography low dose simulations in a prospective intra-individual in-vivo real low dose animal study on a 3rd generation dual-source scanner - Andreas Brendlin, Tübingen / DE
08:00
10
Optimal keV in virtual monoenergetic imaging reconstructions for the detection of hypovascularized liver metastases on a novel photon counting dual-source CT scanner: initial experience - Josua Decker, Augsburg / DE
08:00
11
Feasibility and dose evaluation of a dynamic liver perfusion CT protocol with latest generation scanner - Federica Ullo, Torino / IT